Inovio Pharmaceuticals Inc. (INO)

4.99
NASDAQ : Health Technology
Prev Close 5.04
Day Low/High 4.91 / 5.12
52 Wk Low/High 3.76 / 9.86
Avg Volume 993.90K
Exchange NASDAQ
Shares Outstanding 90.96M
Market Cap 454.81M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Inovio Closes License And Collaboration Agreement with ApolloBio To Develop And Commercialize VGX-3100 In Greater China

Inovio Closes License And Collaboration Agreement with ApolloBio To Develop And Commercialize VGX-3100 In Greater China

Inovio will immediately receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on future sales

Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

INO-1800 shows ability to activate and expand CD8+ killer T cells

Two Exits and an Initiation

We’re cleaning house of Three-rated Inovio Pharma and Pixelworks and starting a small position in ancillary cannabis play Kush Bottles.

Inovio Pharmaceuticals Stock Sees Short Interest Increase 13%

Inovio Pharmaceuticals Stock Sees Short Interest Increase 13%

The most recent short interest data has been released for the 02/15/2018 settlement date, which shows a 1,234,538 share increase in total short interest for Inovio Pharmaceuticals Inc. , to 10,650,607, an increase of 13.11% since 01/31/2018.

Stocks Under $10 Weekly Summary

During a shortened trading week we closed out of one position and added to another after earnings reports.

First Week of April 20th Options Trading For Inovio Pharmaceuticals (INO)

First Week of April 20th Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the April 20th expiration.

Stocks Under $10 Weekly Summary

We shed two positions last week as the market roared back.

Stocks Under $10 Weekly Summary

We added to several positions on weakness during a challenging last week for the stock market.

Stocks Under $10 Weekly Summary

We exited one position and added to another as volatility returned to the stock market last week.

Stocks Under $10 Weekly Summary

It was a mixed week for the portfolio as we trimmed one position and added to the Bullpen.

Why We Added JetPay to the Bullpen

This Berwyn, Pennsylvania firm has interesting prospects.

First Week of March 16th Options Trading For Inovio Pharmaceuticals (INO)

First Week of March 16th Options Trading For Inovio Pharmaceuticals (INO)

Investors in Inovio Pharmaceuticals Inc. saw new options begin trading this week, for the March 16th expiration.

Trimming a Biotech Position

I no longer trust the stock of Inovio Pharmaceuticals, as an investor.

Stocks Under $10 Weekly Summary

Last week, we closed a position for a large gain and used some of the proceeds to start a small stake in a fracking and desalination name.

Inovio's Co-Founder Along With Its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents For 2016

Inovio's Co-Founder Along With Its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents For 2016

Dr. David B. Weiner, Inovio co-founder, and Dr. Jian Yan, Lead Antigen Designer, recognized for their innovative medical and scientific research which led to more than 20 granted U.S. patents in one year

Stocks Under $10 Weekly Summary

We added two new positions to the portfolio last week.

Stocks Under $10 Weekly Summary

Despite a shortened trading week, we made a series of moves, including initiating a position in GSV Capital.

Inovio Receives Milestone Payment From MedImmune As MEDI0457 And Checkpoint Inhibitor Combination Trial In Head And Neck Squamous Cell Cancer Advances To Phase 2

Inovio Receives Milestone Payment From MedImmune As MEDI0457 And Checkpoint Inhibitor Combination Trial In Head And Neck Squamous Cell Cancer Advances To Phase 2

First efficacy trial to evaluate Inovio's cancer immunotherapy targeting HPV in combination with durvalumab

Trimming a Biotech; Adding 2 Bullpen Names

We'll sell some Inovio Pharma on recent strength and put 2 'pot names,' Kush Bottles and Corbus Pharmaceuticals, in the Bullpen.

Stocks Under $10 Weekly Summary

During a quiet week for the market, we added to two positions and trimmed three others.

Inovio Enters License And Collaboration Agreement with ApolloBio To Develop And Commercialize VGX-3100 In Greater China

Inovio Enters License And Collaboration Agreement with ApolloBio To Develop And Commercialize VGX-3100 In Greater China

Inovio to receive $23 million in upfront payment; an additional $20 million in future regulatory milestone payments and double-digit tiered royalties on sales

TheStreet Quant Rating: D (Sell)